Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 6/20 | 0.66 |
| ▸ | KMT2A | Q03164 | 6/20 | 0.66 |
| ▸ | NPC1 | O15118 | 5/20 | 0.66 |
| ▸ | RAB9A | P51151 | 5/20 | 0.66 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.66 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.62 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.62 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.62 |
| ▸ | POLB | P06746 | 1/20 | 0.56 |
| ▸ | LMNA | P02545 | 1/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.54 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.54 |
| ▸ | PTPN1 | P18031 | 2/20 | 0.53 |
| ▸ | MAPT | P10636 | 1/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20511418 | 0.86 | MEN1 (0.62) | MEN1KMT2ANPC1RAB9ASMN1; SMN2 | |
| SCHEMBL513749 | 0.82 | NPC1 (0.62) | MEN1KMT2ANPC1RAB9ASMN1; SMN2 | |
| SCHEMBL513743 | 0.81 | NPC1 (0.61) | MEN1KMT2ANPC1RAB9ASMN1; SMN2 | |
| SCHEMBL515257 | 0.81 | NPC1 (0.61) | MEN1KMT2ANPC1RAB9ASMN1; SMN2 | |
| SCHEMBL1252918 | 0.81 | KMT2A (0.64) | MEN1KMT2ANPC1RAB9ASMN1; SMN2 | |
| SCHEMBL20495063 | 0.80 | MEN1 (0.59) | MEN1KMT2ANPC1RAB9ASMN1; SMN2 | |
| SCHEMBL3957352 | 0.80 | CYP2C19 (0.60) | MEN1KMT2ANPC1RAB9ASMN1; SMN2 | |
| SCHEMBL513780 | 0.80 | PTPN1 (0.61) | MEN1KMT2ANPC1RAB9ASMN1; SMN2 | |
| SCHEMBL10341802 | 0.80 | NPC1 (0.58) | MEN1KMT2ANPC1RAB9ASMN1; SMN2 | |
| SCHEMBL9700935 | 0.80 | KMT2A (0.58) | MEN1KMT2ANPC1RAB9ASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2420493-A1 | HALOALKYLSULFONANILIDE DERIVATIVE | Nissan Chemical Industries, Ltd. (JP) | 2012-02-22 | — | — | EP | disclosed |
| US-20120029187-A1 | HALOALKYLSULFONANILIDE DERIVATIVE | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 2012-02-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120029187-A1 | HALOALKYLSULFONANILIDE DERIVATIVE | CBR3, CBR1, HDHD5 | MEN1 3226/4885KMT2A 1766/4885NPC1 3114/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.